Found 10 matching trials
Study of OTO-104 in Subjects With Unilateral Meniere's Disease
PHASE3The purpose of this study is to evaluate the effectiveness of OTO-104 for t...
Location
Many sites in US. Refer to the contact info listed below.
Phase 3 Study of OTO-104 in Subjects With Unilateral Meniere's Disease
PHASE3The purpose of this study is to evaluate the effectiveness of OTO-104 for t...
Location
Central California Clinical Research
Study of OTO-104 in Subjects at Risk From Cisplatin-Induced Hearing Loss
PHASE2This is a multicenter, Phase 2 study to assess the feasibility, safety and ...
Location
Contact Otonomy call center for trial locations
OTO-104 for Meniere's Disease
PHASE1The purpose of this study is to evaluate the safety of OTO-104 in subjects ...
Location
House Ear Institute
A 6-Month Extension Study of OTO-104 in Meniere's Disease
PHASE3This is an open-label extension study of a single intratympanic injection o...
Location
Many sites in Europe. Refer to the contact info listed below.
A 1-Year Safety Study of OTO-104 in Subjects With Unilateral Meniere's Disease Located in United Kingdom
PHASE2This is a 2-part study of OTO-104 in subjects with unilateral Meniere's dis...
Location
Heatherwood & Wexham Park Hospitals
OTO-104 for the Treatment of Meniere's Disease
PHASE2The purpose of this study is to evaluate the effectiveness of OTO-104 for t...
Location
Many sites in US and Canada. Refer to the contact info listed below.
Open Label Study of OTO-104 in Subjects With Meniere's Disease
PHASE2This is a 1-year, multicenter, Phase 2, open-label safety study in subjects...
Location
Call Otonomy call center for trial locations
Study of OTO-104 in Subjects With Unilateral Meniere's Disease
PHASE3The purpose of this study is to evaluate the effectiveness of OTO-104 for t...
Location
Many sites in Europe. Refer to the contact info listed below.
A 6-Month Extension Study of OTO-104 in Meniere's Disease
PHASE3This is an open-label extension study of a single intratympanic injection o...
Location
Many sites in US. Refer to the contact info listed below.